Literature DB >> 6090750

Karyotypic differences between primary cultures and cell lines from tumors with the human T-cell leukemia virus.

P C Nowell, J B Finan, J W Clark, P S Sarin, R C Gallo.   

Abstract

Chromosome abnormalities were studied in primary cultures and in established T-cell lines from patients with human T-cell leukemia virus (HTLV)-positive leukemia or lymphoma. The present findings, and data from other laboratories, indicated that primary cultures of the HTLV-positive neoplastic cells nearly always showed a chromosomally abnormal clone, whereas most established cell lines had an apparently normal karyotype. These differences included circumstances in which the same blood specimen was used for both types of culture or in which separate specimens were obtained within a short time span. These observations indicated that many cell lines from HTLV-positive leukemia or lymphoma may be derived from nonneoplastic T-cells that were transformed in vitro by the leukemia virus; human T-cells newly infected with HTLV were suggested to have an in vitro growth advantage over the HTLV-infected tumor cells.

Entities:  

Mesh:

Year:  1984        PMID: 6090750

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  3 in total

1.  Chromosomal localization of HTLV-1 viral integration sites using in situ hybridization: detection of a novel IL2R fragment.

Authors:  M J Macera; P Szabo; R S Verma
Journal:  Mol Gen Genet       Date:  1992-09

2.  Chromosomal abnormalities in adult T-cell leukemia/lymphoma (ATL). A report of six cases with review of the literature.

Authors:  R S Verma; M J Macera; M Krishnamurthy; J Abramson; S Kapelner; H Dosik
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Configuration and expression of the T cell receptor beta chain gene in human T-lymphotrophic virus I-infected cells.

Authors:  R F Jarrett; H Mitsuya; D L Mann; J Cossman; S Broder; M S Reitz
Journal:  J Exp Med       Date:  1986-02-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.